Synthetic Biologics, Inc.


ZAG-S&W advised A.G.P./Alliance Global Partners, as sole bookrunner, in Synthetic Biologics’ $18.6 million offering of common stock and preferred stock warrants.

Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients.

The team included Oded Har-Even and Robert Condon.

Recent Activity